2012
Vaccine research and development
Hecht R, Jamison D, Augenstein J, Partridge G, Thorien K. Vaccine research and development. 2012, 299-334. DOI: 10.1017/cbo9781139236805.009.Peer-Reviewed Original ResearchAIDS vaccineInternational AIDS Vaccine InitiativeAnti-retroviral therapyImmune deficiency syndromeAIDS vaccine developmentTime AIDSHIV infectionDeficiency syndromeVaccine researchNew infectionsVaccine InitiativeVaccine developmentTreatment programInfectious diseasesVaccineInfectionPercent efficacyAIDSPreventionEpidemicTreatmentYearsPercentUniversal accessHIVFinancing vaccinations – The South African experience
Blecher MS, Meheus F, Kollipara A, Hecht R, Cameron NA, Pillay Y, Hanna L. Financing vaccinations – The South African experience. Vaccine 2012, 30: c79-c86. PMID: 22939027, DOI: 10.1016/j.vaccine.2012.04.042.Peer-Reviewed Original ResearchConceptsNew vaccinesNew vaccinationsNational vaccination policyBurden of diseaseHealth Economic CriteriaNew generation vaccinesNational advisory groupDepartment of HealthRotavirus diarrheaPneumococcal diseaseVaccination policyVaccinationGeneration vaccinesVaccineGlobal guidelinesEarly introductionInitial donationNumber of livesDiseaseInternational expertsAdvisory GroupFivefold increaseHealthNational spendingMorbidity
2011
An Analysis Of How The GAVI Alliance And Low- And Middle-Income Countries Can Share Costs Of New Vaccines
Saxenian H, Cornejo S, Thorien K, Hecht R, Schwalbe N. An Analysis Of How The GAVI Alliance And Low- And Middle-Income Countries Can Share Costs Of New Vaccines. Health Affairs 2011, 30: 1122-1133. PMID: 21653966, DOI: 10.1377/hlthaff.2011.0332.Peer-Reviewed Original Research
2007
The Impact Of An AIDS Vaccine In Developing Countries: A New Model And Initial Results
Stover J, Bollinger L, Hecht R, Williams C, Roca E. The Impact Of An AIDS Vaccine In Developing Countries: A New Model And Initial Results. Health Affairs 2007, 26: 1147-1158. PMID: 17630459, DOI: 10.1377/hlthaff.26.4.1147.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAIDS VaccinesDeveloping CountriesDisease SusceptibilityDrug EvaluationFemaleHIV InfectionsHumansIncidenceMaleMiddle AgedModels, StatisticalPatient SelectionProbabilityResearch Support as TopicRisk AssessmentRisk FactorsRisk-TakingSexual BehaviorSubstance Abuse, Intravenous